Author

Yinxiang Wang

Observed institution: Nanchang University

ORCID: 0009-0006-9039-9263

Observed ORCID: 0009-0006-9039-9263

OpenAlex ID: A5034104336

Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors

2012 · Shaojing Hu, Guojian Xie, et al. · Bioorganic & Medicinal Chemistry Letters · 60

Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment

2024 · Cunbo Ma, Di Kang, et al. · Journal of Medicinal Chemistry · 24

JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

2025 · Di Kang, Yanping Wang, et al. · Clinical Cancer Research · 16

Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRASG12C

2025 · Amin Li, Sujing Li, et al. · Journal of Medicinal Chemistry · 15

Functional properties and flavor characteristics of milk from cows supplemented with jujube powder

2023 · Chen Zhang, Jie Mei, et al. · Journal of Dairy Science · 11

Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2025 · Peng Wang, Xin Sun, et al. · Cancer Research Communications · 9

Table S7 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S9 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S2 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S10 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S4 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S6 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S8 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S11 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Figure S1 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S12 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S3 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S5 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Table S1 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

2026 · Peng Wang, Xin Sun, et al.

Supplementary Table S2 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

2025 · Di Kang, Yanping Wang, et al.

Supplementary Figure S4 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

2025 · Di Kang, Yanping Wang, et al.

Supplementary Figure S7 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

2025 · Di Kang, Yanping Wang, et al.

Supplementary Figure S9 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

2025 · Di Kang, Yanping Wang, et al.

Data from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

2025 · Di Kang, Yanping Wang, et al.

Supplementary Figure S6 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

2025 · Di Kang, Yanping Wang, et al.

Works count: 54

Citation count: 135

H-index: 6

I10-index: 5